(S)-(+)-1-苄氧基-2-丙醇 | 13807-91-5

• 物质功能分类: 有机原料 - 醇、酚、酚醇类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (S)-(+)-1-苄氧基-2-丙醇
• 中文别名: (S)-1-苄氧基-2-丙醇；苯基(S)-(+)-2-羟基丙醚；(S)-1-O-苄基丙二醇
• 英文名称: (2S)-1-(benzyloxy)propan-2-ol
• 英文别名: (s)-(-)-1-Benzyloxy-2-propanol；(S)-(+)-1,2-Propanediol 1-benzyl ether；(S)-(+)-1-benzyloxy-2-propanol；(S)-(+)-1-benzyloxypropan-2-ol；(2S)-1-(benzyloxy)-2-propanol；(S)-1-(benzyloxy) propan-2-ol；(2S)-1-phenylmethoxypropan-2-ol
• CAS: 13807-91-5；89401-28-5；103129-25-5；85483-97-2
• 化学式: C₁₀H₁₄O₂
• 分子量: 166.22
• InChiKey: KJBPYIUAQLPHJG-VIFPVBQESA-N

物化性质

• 沸点：
  130-132℃ (14 Torr)
• 密度：
  1.044 g/mL at 25 °C (lit.)
• 闪点：
  228 °F
• 稳定性/保质期：
  在常温常压下，该物质是稳定的。

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2909499000
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
: (R)-(−)-1-Benzyloxy-2-propanol
Product name

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
According to Regulation (EC) No1272/2008
Acute toxicity, Oral (Category 4)
Skin irritation (Category 2)
Eye irritation (Category 2)
Specific target organ toxicity - single exposure (Category 3)
According to European Directive 67/548/EEC as amended.
Harmful if swallowed. Irritating to eyes, respiratory system and skin.
Label elements
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/fume/gas/mist/vapours/spray.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Hazard symbol(s)
Xn Harmful
R-phrase(s)
R22 Harmful if swallowed.
R36/37/38 Irritating to eyes, respiratory system and skin.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S36 Wear suitable protective clothing.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Synonyms : (R)-1-O-Benzylpropylene glycol
Formula : C10H14O2
Molecular Weight : 166,22 g/mol
CAS-No. EC-No. Index-No. Classification Concentration
(R)-(-)-1-Benzyloxy-2-propanol
89401-28-5 - - Acute Tox. 4; Skin Irrit. 2; Eye -
Irrit. 2; STOT SE 3; H302,
H315, H319, H335
Xn, R22 - R36/37/38
For the full text of the H-Statements mentioned in this Section, see Section 16.

---

Section 4. FIRST AID MEASURES
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing give artificial respiration Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

---

Section 5. FIRE-FIGHTING MEASURES
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special protective equipment for fire-fighters
Wear self contained breathing apparatus for fire fighting if necessary.

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions
Use personal protective equipment. Avoid breathing vapors, mist or gas. Ensure adequate ventilation.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in suitable, closed
containers for disposal.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
Normal measures for preventive fire protection.
Conditions for safe storage
Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Containers which are
opened must be carefully resealed and kept upright to prevent leakage.
Recommended storage temperature: 2 - 8 °C

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Personal protective equipment
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator with
multi-purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup to
engineering controls. If the respirator is the sole means of protection, use a full-face supplied air
respirator. Use respirators and components tested and approved under appropriate government
standards such as NIOSH (US) or CEN (EU).
Hand protection
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the
standard EN 374 derived from it.
Handle with gloves.
Eye protection
Face shield and safety glasses
Skin and body protection
Choose body protection according to the amount and concentration of the dangerous substance at the
work place.
Hygiene measures
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at
the end of workday.

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Appearance
Form liquid
Colour colourless
Safety data
pH no data available
Melting point no data available
Boiling point no data available
Flash point > 109,9 °C
Ignition temperature no data available
Lower explosion limit no data available
Upper explosion limit no data available
Density 1,027 g/cm3 at 25 °C
Water solubility no data available
Partition coefficient: log Pow: 1,621
n-octanol/water

---

Section 10. STABILITY AND REACTIVITY
Chemical stability
Stable under recommended storage conditions.
Conditions to avoid
no data available
Materials to avoid
Strong oxidizing agents
Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides

---

Section 11. TOXICOLOGICAL INFORMATION
Acute toxicity
no data available
Inhalation: no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.
Ingestion Harmful if swallowed.
Skin May be harmful if absorbed through skin. Causes skin irritation.
Eyes Causes eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly
investigated.
Additional Information
RTECS: no data available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Product
Observe all federal, state, and local environmental regulations. Contact a licensed professional waste
disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn
in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
ADR/RID
Not dangerous goods
IMDG
Not dangerous goods
IATA
Not dangerous goods

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (S)-(+)-1-苄氧基-2-丙醇 在 吡啶 、 potassium tert-butylate 作用下， 反应 4.17h， 生成 (R)-4-Benzyloxy-2-tert-butoxycarbonyl-3-methylbutansaeure-tert-butylester
  参考文献：
  名称：

  Eine neue Synthese von (S)-β-Methyl-γ-butyrolacton und (S)-4-Benzyloxy-3-methylbutansäure

  摘要：

  一种新的(S)-β-甲基-γ-丁内酯和(S)-4-苄氧基-3-甲基丁酸的立体选择性合成方法已经阐述。两种化合物均以廉价的L-乙基乳酸为起始原料，分别获得了26%和30%的总收率。这些产物是有价值的手性构建模块。

  DOI：

  10.1055/s-1991-26584
• 作为产物：
  描述：

  (S)-苄氧甲基环氧乙烷 在 二(五氟苯基)硼酸 、 四甲基二硅氮烷 作用下， 以 二氧六环-d8 为溶剂， 以67%的产率得到(S)-(+)-1-苄氧基-2-丙醇
  参考文献：
  名称：

  Piers硼烷介导的环氧化物和环醚的氢化硅烷化†

  摘要：

  我们报道了环氧化物和环醚的第一个二芳基硼烷催化的氢化硅烷化反应。在环氧化物存在下与氢硅烷原位生成Piers's硼烷（C 6 F 5）2 BH的机理研究表明，烷氧基（二芳基）硼烷（C 6 F 5）2 BOR易于形成为催化活性物质用于环氧化物和环醚的外球氢化硅烷化。

  DOI：

  10.1039/c8cc03741h

文献信息

• SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF
  申请人：Lampe Thomas

  公开号：US20110166163A1

  公开（公告）日：2011-07-07

  The present application relates to novel substituted furopyrimidine derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular diseases.

  本申请涉及新型的取代呋喃嘧啶衍生物，及其制备过程，用于治疗和/或预防疾病，以及用于制备用于治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病。
• Small Molecule Inhibitors of KRAS G12C Mutant
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20210122764A1

  公开（公告）日：2021-04-29

  The disclosure provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein W 1 , W 2 , Y, Z, M, L, C y , C z , R 1 , R 2 , R 3 , R 4 , R 2a , R y , R z and the subscripts m, n, q, and r are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

  该披露提供了Formula (I)的化合物或其药用盐，其中W1、W2、Y、Z、M、L、Cy、Cz、R1、R2、R3、R4、R2a、Ry、Rz以及下标m、n、q和r如本文所述。这些化合物或其药用盐可以抑制Kirsten大鼠肉瘤（KRAS）蛋白的G12C突变体，并有望作为治疗剂具有用途，例如用于治疗癌症。该披露还提供了包含Formula (I)的化合物或其药用盐的药物组合物。该披露还涉及使用这些化合物或其药用盐在癌症的治疗和预防中的方法，以及为此目的制备药物。
• Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof
  申请人：Lampe Thomas

  公开号：US20090318475A1

  公开（公告）日：2009-12-24

  The present application relates to novel, acyclically substituted furopyrimidine derivatives, methods for their production, their use for the treatment and/or prophylaxis of diseases and their use for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular diseases.

  本申请涉及新颖的、非环式取代的呋噻嘧啶衍生物，其生产方法，它们用于治疗和/或预防疾病以及用于生产治疗和/或预防疾病的药物制剂，特别是用于治疗和/或预防心血管疾病。
• [EN] PYRROLOTRIAZINE DERIVATIVES FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES<br/>[FR] DÉRIVÉS DE PYRROLOTRIAZINE POUR LE TRAITEMENT DE MALADIES MÉDIÉES PAR KIT ET PDGFRA
  申请人：BLUEPRINT MEDICINES CORP

  公开号：WO2020210293A1

  公开（公告）日：2020-10-15

  The present disclosure provides compounds of Formula I, pharmaceutical salts thereof, and/or solvates of any of the foregoing which are useful for treating diseases and conditions related to mutant KIT and PDGFRa and present an advantageously non-brain penetrant profile for treating diseases and conditions related to mutant KIT and PDGFRa. The present disclosure also provides methods for treating gastrointestinal stromal tumors and systemic mastocytosis.

  本发明公开了式I化合物、其药用盐以及上述任何化合物的溶剂合物，它们可用于治疗与突变型KIT和PDGFRα相关的疾病和病症，并且对于治疗与突变型KIT和PDGFRα相关的疾病和病症具有有利的非脑渗透性特征。本发明还提供了治疗胃肠道间质瘤和系统性肥大细胞增多症的方法。
• [EN] MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] MODULATEURS DU RÉCEPTEUR DE GPR119 ET TRAITEMENT DE TROUBLES ASSOCIÉS
  申请人：ARENA PHARM INC

  公开号：WO2011127051A1

  公开（公告）日：2011-10-13

  The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as a single agent or in combination with one or more additional pharmacetical agents, such as, an inhibitor of DPP-IV, a biguanide, an SGLT2 inhibitor, or an alpha-glucosidase inhibitor, in the treatment of, for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing a blood incretin level; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.

  本发明涉及式(Ia)的化合物及其药学上可接受的盐、溶剂和水合物，这些化合物可作为单一药剂或与一个或多个额外的药剂（如DPP-IV抑制剂、双胍类药物、SGLT2抑制剂或α-葡萄糖苷酶抑制剂）结合使用，在治疗中发挥作用，例如治疗选择自：GPR119受体相关疾病；通过增加血液胰高血糖素水平改善的病症；与代谢相关的疾病；2型糖尿病；肥胖；以及相关并发症。